Journal
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
Volume 64, Issue 3, Pages 179-189Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1369/0022155415626499
Keywords
aged; cortical bone; joint; osteocyte subtype; hypertrophic chondrocyte; articular cartilage
Categories
Funding
- National Institutes of Health [NS23970]
- National Cancer Institute [CA157449, CA1574550]
- Calhoun Fund for Bone Pain
Ask authors/readers for more resources
Sclerostin is a 24-kDa secreted glycoprotein that has been identified as a negative modulator of new bone formation and may play a major role in age-related decline in skeletal function. Although serum levels of sclerostin markedly increase with age, relatively little is known about whether cells in the skeleton change their expression of sclerostin with aging. Using immunohistochemistry and confocal microscopy, we explored sclerostin immunoreactivity (sclerostin-IR) in the femurs of 4-, 9-, and 24-month-old adult C3H/HeJ male mice. In the femur, the only two cell types that expressed detectable levels of sclerostin-IR were bone osteocytes and articular cartilage chondrocytes. At three different sites along the diaphysis of the femur, only a subset of osteocytes expressed sclerostin-IR and the percentage of osteocytes that expressed sclerostin-IR increased from approximately 36% to 48% in 4- vs. 24-month-old mice. In marked contrast, in the same femurs, there were similar to 40% fewer hypertrophic chondrocytes of articular cartilage that expressed sclerostin-IR when comparing 24- vs. 4-month-old mice. Understanding the mechanism(s) that drive these divergent changes in sclerostin-IR may provide insight into understanding and treating the age-related decline of the skeleton.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available